Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy

Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy

You Ke,1 Cheng Xiang2 1Department of Nephrology, The Second Affiliated Hospital of Zhejiang University, Hangzhou, China; 2Department of Surgery, The Second Affiliated Hospital of Zhejiang University, Hangzhou, China Background: Thyroid cancer becomes the most common endocrine cancer with the great...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ke Y, Xiang C
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
Sorafenib
RAI-refractory DTC
Hollow mesoporous silica nanoparticles
Transferrin
RAF/MEK/ERK
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/982fc76b45f340d6a995fcae8a006fdd
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:982fc76b45f340d6a995fcae8a006fdd
record_format dspace
spelling oai:doaj.org-article:982fc76b45f340d6a995fcae8a006fdd2021-12-02T06:07:14ZTransferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy1178-2013https://doaj.org/article/982fc76b45f340d6a995fcae8a006fdd2018-12-01T00:00:00Zhttps://www.dovepress.com/transferrin-receptor-targeted-hmsn-for-sorafenib-delivery-in-refractor-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013You Ke,1 Cheng Xiang2 1Department of Nephrology, The Second Affiliated Hospital of Zhejiang University, Hangzhou, China; 2Department of Surgery, The Second Affiliated Hospital of Zhejiang University, Hangzhou, China Background: Thyroid cancer becomes the most common endocrine cancer with the greatest growing incidence in this decade. Sorafenib is a multikinase inhibitor for the treatment of progressive radioactive iodine-refractory differentiated thyroid cancer (DTC), while the off-target toxicity effect is usually inconvenient for patients taking. Methods: In this study, hollow mesoporous silica nanoparticles (HMSNs) with transferrin modification (Tf-HMSNs) were loaded with sorafenib (sora@Tf-HMSNs) to help targeted delivery of sorafenib. Due to the biocompatible Tf shell, Tf-HMSNs exhibited excellent biocompatibility and increased intracellular accumulation, which improved the targeting capability to cancer cells in vitro and in vivo. Results: Sora@Tf-HMSNs treatment exhibited the strongest inhibition effect of res-TPC-1 cells and res-BCPAP cells compared with sora@HMSNs and sorafenib groups and induced more cancer cell apoptosis. Finally, Western blot analysis was conducted to check the expression of RAF/MEK/ERK signaling pathway after sorafenib encapsulated Tf-HMSNs treatment. Conclusion: Overall, sora@Tf-HMSNs can significantly increase the effective drug concentration in cancer cells and thus enhance the anticancer effect, which are expected to be promising nanocarriers to deliver anticancer drugs for effective and safe therapy for RAI-refractory DTC. Keywords: sorafenib, RAI-refractory DTC, hollow mesoporous silica nanoparticles, transferrin, RAF/MEK/ERKKe YXiang CDove Medical PressarticleSorafenibRAI-refractory DTCHollow mesoporous silica nanoparticlesTransferrinRAF/MEK/ERKMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 13, Pp 8339-8354 (2018)
institution DOAJ
collection DOAJ
language EN
topic Sorafenib
RAI-refractory DTC
Hollow mesoporous silica nanoparticles
Transferrin
RAF/MEK/ERK
Medicine (General)
R5-920
spellingShingle Sorafenib
RAI-refractory DTC
Hollow mesoporous silica nanoparticles
Transferrin
RAF/MEK/ERK
Medicine (General)
R5-920
Ke Y
Xiang C
Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy
description You Ke,1 Cheng Xiang2 1Department of Nephrology, The Second Affiliated Hospital of Zhejiang University, Hangzhou, China; 2Department of Surgery, The Second Affiliated Hospital of Zhejiang University, Hangzhou, China Background: Thyroid cancer becomes the most common endocrine cancer with the greatest growing incidence in this decade. Sorafenib is a multikinase inhibitor for the treatment of progressive radioactive iodine-refractory differentiated thyroid cancer (DTC), while the off-target toxicity effect is usually inconvenient for patients taking. Methods: In this study, hollow mesoporous silica nanoparticles (HMSNs) with transferrin modification (Tf-HMSNs) were loaded with sorafenib (sora@Tf-HMSNs) to help targeted delivery of sorafenib. Due to the biocompatible Tf shell, Tf-HMSNs exhibited excellent biocompatibility and increased intracellular accumulation, which improved the targeting capability to cancer cells in vitro and in vivo. Results: Sora@Tf-HMSNs treatment exhibited the strongest inhibition effect of res-TPC-1 cells and res-BCPAP cells compared with sora@HMSNs and sorafenib groups and induced more cancer cell apoptosis. Finally, Western blot analysis was conducted to check the expression of RAF/MEK/ERK signaling pathway after sorafenib encapsulated Tf-HMSNs treatment. Conclusion: Overall, sora@Tf-HMSNs can significantly increase the effective drug concentration in cancer cells and thus enhance the anticancer effect, which are expected to be promising nanocarriers to deliver anticancer drugs for effective and safe therapy for RAI-refractory DTC. Keywords: sorafenib, RAI-refractory DTC, hollow mesoporous silica nanoparticles, transferrin, RAF/MEK/ERK
format article
author Ke Y
Xiang C
author_facet Ke Y
Xiang C
author_sort Ke Y
title Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy
title_short Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy
title_full Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy
title_fullStr Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy
title_full_unstemmed Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy
title_sort transferrin receptor-targeted hmsn for sorafenib delivery in refractory differentiated thyroid cancer therapy
publisher Dove Medical Press
publishDate 2018
url https://doaj.org/article/982fc76b45f340d6a995fcae8a006fdd
work_keys_str_mv AT key transferrinreceptortargetedhmsnforsorafenibdeliveryinrefractorydifferentiatedthyroidcancertherapy
AT xiangc transferrinreceptortargetedhmsnforsorafenibdeliveryinrefractorydifferentiatedthyroidcancertherapy
_version_ 1718400065310031872

Ejemplares similares